|
?:abstract
|
-
BACKGROUND/AIM: We aimed to identified clinical settings of renal transplant patients with COVID-19 Material and methods: In this retrospective study, we included kidney transplant inpatients with laboratory confirmed COVID-19 who had been discharged or had died by October 1, 2020 Characteristics of the patients, basal and last outpatient biochemical parameters of the patients were recorded Discontinuation or dosage reduction of immunosuppressives and other treatment information were documented RESULTS: 20 patients were included in this study, of whom 18 were discharged and 2 died in hospital The mean duration of hospitalization and follow-up were 9 7 ± 6 4 day and 4 5 ± 2 0 months, respectively 14 (70%) were male, mean age was 48 0±10 3 years At admission, all had immunosuppression withdrawn and were started on methylprednisolone 16 mg/day (50%) or dexamethasone (50%) Tacrolimus/m-TOR inhibitors were reduced by 50% and all antimetabolites were discontinued Hemodialysis was needed for 10% of patients Acute kidney injury was detected in 25% of the patients With respect to hospitalization time and complications, there was no significant difference between dexamethasone users and those who did not (p>0 05) The discontinued immunosupressives were resumed within 2-4 weeks after discharge according to severity of disease No re-hospitalization or acute rejection was detected during the follow-up of the patients CONCLUSION: Renal transplant patients are considered a high risk group for COVID-19 It can be said that discontinuation or reduction dosages of immunosuppressives may be an effective and safe in kidney transplant patients
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}